Gary W. Pace, Ph.D.
Dr. Gary W. Pace has been a director since 2020 and is a seasoned biopharmaceutical executive with over 40 years of experience in the industry. He has co-founded several early-stage life science companies, where he built products from the laboratory to commercialization and is currently actively involved with several private companies. He has served on the boards of several public companies including, Pacira Biosciences Inc. from 2008 to 2024, Antisense Therapeutics Ltd. from 2015 to 2022, Simavita Ltd. from 2016 to 2022, ResMed Inc. from 1994 to 2018, Transition Therapeutics Inc. from 2002 to 2016, and ORxPharma Ltd. from 2001 to 2013. Dr. Pace has contributed to the development of the biotechnology industry through honorary university appointments and industry and government committees. In 2003, he was awarded a Centenary Medal by the Australian Government “for service to Australian society in research and development” and was recognized as the 2011 Director of the Year (corporate governance) by the San Diego Directors Forum. Dr. Pace holds a B.Sc. (Hons I) from the University of New South Wales and a Ph.D. from the Massachusetts Institute of Technology where he was a Fulbright Fellow and General Foods Scholar. The Board believes that Dr. Pace’s years of experience providing strategic advisory services to complex organizations, including as a public company director provides him with the qualifications and skills to serve as a director.